<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Betari N</submitter><funding>Stiftelsen Kristian Gerhard Jebsen</funding><funding>Norges Forskningsråd</funding><funding>Horizon 2020 Framework Programme</funding><funding>Knut och Alice Wallenbergs Stiftelse</funding><funding>Federación Española de Enfermedades Raras</funding><pagination>593416</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7726444</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11</volume><pubmed_abstract>Serotonin (5-HT) is a hormone and neurotransmitter that modulates neural activity as well as a wide range of other physiological processes including cardiovascular function, bowel motility, and platelet aggregation. 5-HT synthesis is catalyzed by tryptophan hydroxylase (TPH) which exists as two distinct isoforms; TPH1 and TPH2, which are responsible for peripheral and central 5-HT, respectively. Due to the implication of 5-HT in a number of pathologies, including depression, anxiety, autism, sexual dysfunction, irritable bowel syndrome, inflammatory bowel disease, and carcinoid syndrome, there has been a growing interest in finding modulators of these enzymes in recent years. We thus performed high-throughput screening (HTS) using a fluorescence-based thermal shift assay (DSF) to search th</pubmed_abstract><journal>Frontiers in pharmacology</journal><pubmed_title>Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole-&lt;i>In Vitro&lt;/i> and &lt;i>In Vivo&lt;/i> Investigations.</pubmed_title><pmcid>PMC7726444</pmcid><funding_grant_id>501100005416</funding_grant_id><funding_grant_id>667302</funding_grant_id><funding_grant_id>SKGJ-MED02</funding_grant_id><funding_grant_id>SAF2017-87349-R</funding_grant_id><funding_grant_id>501100004063</funding_grant_id><pubmed_authors>Godoy-Marin H</pubmed_authors><pubmed_authors>Betari N</pubmed_authors><pubmed_authors>Ciruela F</pubmed_authors><pubmed_authors>Morato X</pubmed_authors><pubmed_authors>Sahlholm K</pubmed_authors><pubmed_authors>Teigen K</pubmed_authors><pubmed_authors>Jauregui O</pubmed_authors><pubmed_authors>Haavik J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole-&lt;i>In Vitro&lt;/i> and &lt;i>In Vivo&lt;/i> Investigations.</name><description>Serotonin (5-HT) is a hormone and neurotransmitter that modulates neural activity as well as a wide range of other physiological processes including cardiovascular function, bowel motility, and platelet aggregation. 5-HT synthesis is catalyzed by tryptophan hydroxylase (TPH) which exists as two distinct isoforms; TPH1 and TPH2, which are responsible for peripheral and central 5-HT, respectively. Due to the implication of 5-HT in a number of pathologies, including depression, anxiety, autism, sexual dysfunction, irritable bowel syndrome, inflammatory bowel disease, and carcinoid syndrome, there has been a growing interest in finding modulators of these enzymes in recent years. We thus performed high-throughput screening (HTS) using a fluorescence-based thermal shift assay (DSF) to search th</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2026-05-02T06:31:05.827Z</modification><creation>2021-02-20T16:45:59Z</creation></dates><accession>S-EPMC7726444</accession><cross_references><pubmed>33324221</pubmed><doi>10.3389/fphar.2020.593416</doi></cross_references></HashMap>